Page 3 - Dr Reddy's Laboratories

Dr Reddy's launches wearable device for drug-free management of migraine

In January this year, Dr Reddy's entered an exclusive agreement with Theranica for the marketing and distribution of Nerivio in India

Dr Reddy's Laboratories Q1 PAT up 18% to Rs 1,402 cr on India, Russia biz

With cash surplus of Rs 4980 crore, pharma major looking at inorganic opportunities

Dr Reddy's Labs Q1FY24 results: Net profit up 18% YoY to Rs 1,402.5 cr

As compared to Rs 959.2 crore in the quarter that ended on March 31, the net profit was up 46%

Dr Reddy's application for biosimilar candidate accepted for USFDA's review

Dr Reddy's Laboratories on Wednesday said its biologics licence application for its proposed biosimilar rituximab candidate has been accepted for a substantive review by the US Food and Drug Administration (USFDA). This closely follows acceptance of the rituximab biosimilar dossier for review by two other regulatory agencies -- the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Rituximab is used to treat certain autoimmune diseases and types of cancer. "This milestone underscores our capability for global clinical development of high-quality biosimilar products for highly regulated and global markets," Dr Reddy's Global Head of Biologics Jayanth Sridhar said in a statement. It also reinforces the potential of the product as a safe and effective treatment option for patients across the globe, he added. Development and commercialisation of biological drugs is an important growth lever for the company's business, Sridhar ...

Dr Reddy's Laboratories forays into new terrain to give 'top-5' aim a shot

Analysts think that these new entries may help the company navigate multiple risks in the Indian branded market

Dr Reddy's completes Phase-I study in proposed biosimilar of tocilizumab

Global Phase III study is being initiated to compare the efficacy, safety, tolerability and immunogenicity of DRL_TC with the reference product

Dr Reddy's Laboratories QoQ showing catches a cold on weak US sales

While pharma major has maintained its margin guidance, expensive valuations limit upside

Dr Reddy's Laboratories Q4 PAT grows nine-fold riding on US, India biz

For the full year 2022-23, DRL's revenues were up 15 percent to Rs 24,587.9 crore while the PAT grew by 91 percent to Rs 4,506.7 crore

Dr Reddy's acquires Mayne Pharma's USA prescription portfolio for $105 mn

The acquisition will complement DRL's US retail prescription pharmaceutical business with limited competition products

DRL posts strong 77% profit growth to Rs 1,247 cr riding on US, Russia

Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for them in US in the coming quarters

Sensex slumps 774 pts, Nifty ends below 17900; Auto, FMCG stocks outshine

Stock market LIVE: As per rollover data, the Nifty index has, so far, witnessed rollover in-line with the last three months' averages. However, slight declines in roll cost indicates a capped upside

Stocks to Watch: Wipro, HDFC Bank, DMart, Delhivery, NDTV, Sula Vineyard

Stocks to Watch today: Wipro, after market hours on Friday, reported a consolidated net profit of Rs 3,052 crore for October-December FY23, an increase of 2.8 per cent year-on-year (YoY)

Dr Reddy's acquires trademark rights for Pfizer breast cancer drug

Dr. Reddy's plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on Primcyv

After the anti-diabetic market, India's cardiac market in for a shake-up

After the anti-diabetic market, India's cardiac market in for a shake-up

Inflows in Tata Motors stock may surge as it replace Dr Reddy's in Sensex

Change effective from Dec 19, but adjustment will take place on Dec 16. After DRL's deletion, Sun Pharma will be the only healthcare stock in the index

Dr Reddy's lines up Rs 1,500 cr capex, to focus on biosimilars, injectables

Dr Reddy's Laboratories has earmarked a capex of around Rs 1,500 crore for FY23 with major part of it slated to go into building capacities for its biosimilar and injectable businesses, according to CFO Parag Agarwal. The Hyderabad-based drug major also plans to utilise the capital for adding capacities to existing plants, firm up R&D activities and further invest in digitisation projects. "The capex for the full year is likely to be around Rs 1,500 crore in that range, and a lot of this capex is towards building capacity for our biosimilar business and for our injectable business," the chief financial officer said in an analyst call. He was replying to a query about the company's capex plans for ongoing financial year. "When we say capex, obviously, it is not all going into building new plants. So, there will be several additions to existing plants, there will be maintenance capex, there will be capex on digitalisation projects, on R&D facility. So, it is all put together," .

Strong US pipeline, sustained growth trajectory main trigger for Dr Reddy's

Excluding the strong US show led by Revlimid, Q2 was a mixed bag

Sensex rises 203 pts, Nifty ends near 17,800; Maruti zooms 5%, RIL 3%

Stock market wrap: Reliance alone contributed 231 points to the 30-share benchmark. Maruti, M&M and NTPC were the other major gainers. The Metal and IT sector witnessed selling pressure.

Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Wockhardt likely to sell India business to cut debt, focus on UK: Analysts

Company left with low-margin brands in India after selling profitable ones